Patenting antibodies across different jurisdictions can be a difficult task, as Kathy Coulter, senior IP counsel at Bristol-Myers Squibb, tells LSIPR.
A recent case in India reveals the various ways in which pharmaceutical patents can be challenged, as Neeti Wilson, Arpita Kulshreshtha and Gitika Suri of Anand and Anand report.
While personalised medicine is a challenging area for drug developers, there are a number of potential solutions, as LSIPR finds out.
Lino Almazan-Monroy and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril discuss how inventors seeking patents for polymorphs in Mexico can give themselves the best chance of success.
The Milan Court has issued an important ruling clarifying the rules governing the activities of active pharmaceutical ingredient manufacturers in Italy, as Gabriel Cuonzo and Luca Pellicciari of Trevisan & Cuonzo report.
As the tide of M&A activity continues to rise across the life sciences industry, LSIPR speaks to Tracy MacNeal of Ximedica on what’s driving the trend and the pitfalls to be aware of.
Mark Remus of Brinks Gilson & Lione discusses two patent-related challenges for generic pharmaceutical companies and how they might be overcome.
Frank Kalkbrenner was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
Craig Muir was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the investment section, as LSIPR reports.
The European Commission’s proposed export waiver for supplementary protection certificates is likely to face opposition and may be delayed by EU parliamentary changes, says Trevor Cook of WilmerHale.